Elion Therapeutics, a NYC-based biotechnology company dedicated to advancing the treatment of life-threatening invasive fungal infections (IFIs), closed a $81M Series B funding.
The round was led by Deerfield Management and the AMR Action Fund. Additional investors included Illinois Ventures.
The company intends to use the funds to support the advancement of SF001, a polyene antifungal designed for reduced toxicity.
Led by Kieren Marr, President and Chief Medical Officer, Elion Therapeutics is a biotechnology company dedicated to innovating the treatment of life-threatening IFIs. It is advancing a polyene antifungal rationally designed to mitigate toxicities and potentially transform the future of polyene therapy. Its clinical-stage candidate, SF001, a polyene antifungal, completed a first-in-human single-ascending dose study and is now being evaluated in a multiple-ascending dose study. The active molecule is a novel analog of the antifungal amphotericin B (AmB), rationally designed to mitigate systemic toxicities. In 2023, SF001 received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for early antifungal therapy of presumed invasive fungal disease and treatment of invasive aspergillosis.
FinSMEs
17/06/2024